{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:13:53Z","timestamp":1791980033627,"version":"4.4.0"},"reference-count":88,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T00:00:00Z","timestamp":1535932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>For young adults with acute lymphoblastic leukemia, pediatric\u2010based regimens are likely to provide the following when compared to hyper\u2010CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality\u2010adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper\u2010CVAD regimens for the treatment of Philadelphia\u2010negative B\u2010precursor or T\u2010cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.<\/jats:p>","DOI":"10.1002\/ajh.25229","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T06:54:09Z","timestamp":1532933649000},"page":"1254-1266","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Treatment of young adults with Philadelphia\u2010negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper\u2010CVAD vs. pediatric\u2010inspired regimens"],"prefix":"10.1002","volume":"93","author":[{"given":"Stuart E.","family":"Siegel","sequence":"first","affiliation":[{"name":"Critical Mass Young Adult Cancer Alliance Washington District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Cleveland Ohio and SWOG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Seibel","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute Bethesda Maryland and Children's Oncology Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[{"name":"Department of Medicine Blood and Marrow Transplantation, Stanford University Palo Alto California and SWOG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"University of Chicago Chicago Illinois and The Alliance"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Luger","sequence":"additional","affiliation":[{"name":"University of Pennsylvania Philadelphia Pennsylvania and ECOG\u2010ACRIN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center Tampa Florida and SWOG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute ALL Consortium Dana Farber Cancer Institute Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Freyer","sequence":"additional","affiliation":[{"name":"University of Southern California, Norris Comprehensive Cancer Center Los Angeles California and Children's Oncology Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Southern California Los Angeles California and ECOG\u2010ACRIN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Mary Bridge Children's Hospital and Health Center, National Clinical Oncology Research Program and Tacoma General Hospital Tacoma Washington and SWOG, Children's Oncology Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Hayes\u2010Lattin","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University Portland Oregon and SWOG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Intermountain Healthcare Salt Lake City Utah and SWOG"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry J.","family":"Jaboin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Oregon Health and Science University Portland Oregon and NRG Oncology Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Coccia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics University of Nebraska Medical Center Omaha Nebraska and Children's Oncology Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7738-5146","authenticated-orcid":false,"given":"Archie","family":"Bleyer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Oregon Health and Science University Portland Oregon and Children's Oncology Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,3]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence\u2014SEER 18 Regs Research Data+Hurricane Katrina Impacted Louisiana Cases Nov 2016 Sub (2000\u20102014) <Katrina\/Rita Population Adjustment>\u2014Linked To County Attributes\u2014Total U.S. 1969\u20102015 Counties National Cancer Institute DCCPS Surveillance Research Program released April 2017 based on the November 2016 submission."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26989"},{"key":"e_1_2_8_4_1","unstructured":"Joinpoint Regression Program Version 4.1.1. August2014; Statistical Research and Applications Branch National Cancer Institute."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5305"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890701)64:1<23::AID-CNCR2820640105>3.0.CO;2-T"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4428"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24947"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3514-3"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1328"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008933"},{"issue":"121","key":"e_1_2_8_14_1","article-title":"Frontline\u2010treatment of acute lymphoblastic leukemia in older adolescents and young adults using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (Alliance)","volume":"122","author":"Advani AS","year":"2013","journal-title":"Am Soc Hematol: Blood."},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V114.22.3084.3084","article-title":"Outcome for adolescents and young adults with the hyper\u2010CVAD (with or without rituximab) regimens for de novo acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"114","author":"Thomas DA","year":"2009","journal-title":"Blood."},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605085"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510795"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-9796(03)00072-X"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA10500"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju027"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24419"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22189"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.229"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.7265"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1182\/blood.V128.22.3975.3975","article-title":"Outcome of patients with Philadelphia chromosome\u2010negative acute lymphoblastic leukemia by age group over 35 years: a single institution experience","volume":"128","author":"Sasaki K","year":"2016","journal-title":"Blood"},{"issue":"21","key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults with acute lymphoblastic leukemia: early results of U.S. intergroup trial C10403","volume":"124","author":"Stock W","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e18527"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.06.010"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000375258"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.11.002"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529202"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1513"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1182\/blood.V126.23.3762.3762","article-title":"Poor outcomes with hyper CVAD induction for T\u2010cell lymphoblastic leukemia\/lymphoma","volume":"126","author":"Kota VK","year":"2015","journal-title":"Blood."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12269"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-070342"},{"key":"e_1_2_8_37_1","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1182\/blood.V126.23.794.794","article-title":"Capizzi\u2010style methotrexate with pegasparagase is superior to high\u2010dose methotrexate in T\u2010lineage acute lymphoblastic leukemia: results from Children's oncology group (COG) AALL0434","volume":"126","author":"Winter SS","year":"2015","journal-title":"Blood."},{"key":"e_1_2_8_38_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T\u2010ALL shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end\u2010induction minimal residual disease (MRD) in COG AALL0434","volume":"124","author":"Wood BL","year":"2014","journal-title":"Blood."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5385"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-484592"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24285"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2016.0060"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0488-6"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4544"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217701291"},{"key":"e_1_2_8_47_1","unstructured":"Childhood Cancer Survivor Study.Pregnancy Outcomes: All Pregnancies in Female Survivors or Female Partners of Male Survivors.https:\/\/ccss.stjude.org\/content\/dam\/en_US\/shared\/ccss\/documents\/data\/data-bk-pregnancy-base-m.pdf. Accessed August 1 2017."},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00086-3"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.08.014"},{"key":"e_1_2_8_50_1","unstructured":"Fertility Risk Tool.https:\/\/www.teamlivestrong.org\/we-can-help\/fertility-services\/risks. Accessed February 15 2018."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000351172"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24005"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2011.n.007"},{"key":"e_1_2_8_55_1","unstructured":"Pegaspargase and combination chemotherapy in treating patients with newly diagnosed acute lymphoblastic leukemia.https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01005914?term=01005914&rank=1. Accessed August 4 2018."},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.532889"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1159\/000375258"},{"key":"e_1_2_8_58_1","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood.V118.21.1510.1510","article-title":"Treatment toxicity in adolescents and young adult patients compared with younger patients treated for high risk B\u2010precursor acute lymphoblastic leukemia a report from the Children's oncology group study AALL0232","volume":"118","author":"Larsen EC","year":"2011","journal-title":"Blood."},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.12.013"},{"key":"e_1_2_8_61_1","first-page":"1297","article-title":"Patient and therapy\u2010related factors affecting the toxicity of pegylated\u2010asparaginase for the treatment of adult acute lymphoblastic leukemia","volume":"130","author":"Minetto P","year":"2017","journal-title":"Am Soc Hematol: Blood."},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08524.x"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12600"},{"issue":"2","key":"e_1_2_8_64_1","first-page":"330","article-title":"l\u2010Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia","volume":"100","author":"Appel IM","year":"2008","journal-title":"Thromb Haemost."},{"issue":"11","key":"e_1_2_8_65_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.20452\/pamw.518","article-title":"Use of l\u2010asparaginase in acute lymphoblastic leukemia: recommendations of the group","volume":"118","author":"Piatkowska\u2010Jakubas B","year":"2008","journal-title":"Pol Arch Med Wewn."},{"key":"e_1_2_8_66_1","unstructured":"A study of the safety and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with asparaginase.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02369653?term=apixaban&recrs=ab&cond=leukemia&cntry=US&rank=1. Accessed August 4 2018."},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12166"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.11.010"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.209"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1207"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950230205"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.022"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2016.0049"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e22002"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.7.1916"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.5.744"},{"key":"e_1_2_8_77_1","doi-asserted-by":"crossref","first-page":"5604","DOI":"10.1182\/blood.V126.23.5604.5604","article-title":"Transition of intensive chemotherapy for acute lymphoblastic leukemia to the outpatient setting: analysis of safety and cost savings","volume":"126","author":"Kubal TE","year":"2015","journal-title":"Blood."},{"key":"e_1_2_8_78_1","unstructured":"A phase III trial to evaluate the efficacy of the addition of inotuzumab ozogamicin (a conjugated anti\u2010CD22 monoclonal antibody) to frontline therapy in young adults (ages 18\u201039 years) with newly diagnosed precursor B\u2010cell ALL. NCT03150693https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150693?term=alliance&recrs=ab&cond=acute+lymphoblastic+leukemia&cntry=US&rank=2. Accessed August 4 2018."},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.265"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1206"},{"key":"e_1_2_8_81_1","unstructured":"Total Cost of Cancer Care by Site of Service: Physician office vs outpatient hospital March 2012. Prepared by Avalere Health.https:\/\/www.communityoncology.org\/pdfs\/avalere\u2010cost\u2010of\u2010cancer\u2010care\u2010study.pdf; Accessed August 4 2018."},{"key":"e_1_2_8_82_1","unstructured":"Chemotherapy Average Sales Price Medicare.https:\/\/www.cms.gov\/Medicare\/Medicare\u2010Fee\u2010for\u2010Service\u2010Part\u2010B\u2010Drugs\/McrPartBDrugAvgSalesPrice\/2016ASPFiles.html. Accessed August 4 2018."},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0866"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2012.0112"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0147"},{"issue":"2","key":"e_1_2_8_86_1","first-page":"138","article-title":"Management of acute lymphoblastic leukemia in young adults","volume":"16","author":"Muffly LS","year":"2018","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_8_87_1","first-page":"352","article-title":"Understanding causes of inferior outcome in AYAs with ALL in a real\u2010world setting","volume":"130","author":"Wolfson JA","year":"2017","journal-title":"Am Soc Hematol Blood."},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-778530"},{"issue":"12","key":"e_1_2_8_89_1","first-page":"1080","article-title":"Treatment of acute lymphoblastic leukemia in adults: applying lessons learned in children","volume":"30","author":"Aldoss IT","year":"2016","journal-title":"Oncology (Williston Park)"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T23:09:33Z","timestamp":1751756973000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,3]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/ajh.25229"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25229","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,3]]},"assertion":[{"value":"2018-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}